Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Accepted: 28 August 2022
First Online: 26 September 2022
Declarations
:
: GlaxoSmithKline Biologicals SA funded all costs associated with the development and publication of this letter.
: NG and NL are employees of GSK and hold shares in GSK. MLN is an AIXIAL Group consultant on behalf of GSK. AIXIAL received fees from GSK for this study. The authors declare no other financial and non-financial relationships and activities and no other conflicts of interest.
: All authors participated in the development of this publication and gave final approval before submission.
: Not applicable.
: Not applicable.
: Not applicable.